MD Anderson and Replay announced that the FDA has issued a ‘safe to proceed’ for the Investigational New Drug application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for sarcoma.
news, journals and articles from all over the world.
MD Anderson and Replay announced that the FDA has issued a ‘safe to proceed’ for the Investigational New Drug application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for sarcoma.